Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. OTC
  4. CSLLY

Market Cap: $127.4B

CL

CSL Limited

CSLLY
OTC (Other OTC)USD
Invest in CSLLY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$32.90
-$0.57(-1.70%)
At close: Nov 18, 17:51 EST

More on CSL Limited

  • News & announcements
  • Financials

CSL Limited at a Glance

  • Loss-making over the last 12 months (net margin -16.1%).

Open

$21.46

Prev. Close

$33.47

High

$21.67

Low

$21.46

Key Statistics

52-Week Range81% of range
Low $16.01High $36.88
Market Cap
$127.4B
P/E Ratio
n/m (loss-making)
EPS (TTM)
-$2.64
Revenue (TTM)
$15.74B
Dividend Yield
2.03%
Price / Book
4.35x
Beta
0.08
Avg. Volume
356.7K

Company Profile

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

CEOGordon Naylor DipCompSc
SectorHealthcare
IndustryBiotechnology
Employees29K
IPO DateDec 29, 2009
ExchangeOTC
Exchange NameOther OTC
CurrencyUSD
Headquarters & Contact
Address655 Elizabeth Street
City / State / ZIPMelbourne, VIC, 3000
CountryAustralia
Phone

CSLLY Stock FAQ

What does CSL Limited do?

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China.

Where is CSL Limited stock listed?

CSL Limited trades on the Other OTC under the ticker CSLLY, priced in USD.

What is CSL Limited's market cap?

CSL Limited has a market capitalisation of $127.4B, based on its latest share price.

What is the P/E ratio of CSLLY?

CSLLY has no meaningful P/E ratio because it reported a loss over the last 12 months.

What is CSLLY's 52-week high and low?

Over the past 52 weeks CSLLY has traded between $16.01 and $36.88.

Does CSL Limited pay a dividend?

Yes. CSL Limited's dividend yields 2.03% at the current share price.

Is CSL Limited profitable?

Loss-making over the last 12 months (net margin -16.1%).

Who is the CEO of CSL Limited?

Gordon Naylor DipCompSc is the CEO of CSL Limited, which is headquartered in Melbourne.

Shares trade 0% above a discounted cash flow (DCF) estimate of $32.75.
  • Moderate debt: borrowings are 0.74x shareholders' equity.
  • Comfortable liquidity: 2.2x more short-term assets than short-term liabilities.
  • Pays a dividend yielding 2.03%.
  • Trading 81% of the way between its 52-week low and high.
  • Generated automatically from reported financial data. General information only, not financial advice.

    Fundamentals Scorecard

    Each pillar is scored out of 5 from the latest reported data.

    • Valuation

      Weak · 2.3/5

      Price vs earnings, book value and discounted cash flow.

    • Profitability

      Weak · 1.0/5

      Return on equity and return on assets.

    • Financial Health

      Fair · 3.0/5

      Debt levels and Altman Z-Score bankruptcy risk.

    • Fundamental Trend

      Fair · 2.8/5

      Piotroski F-Score: 9 checks on profit, leverage and efficiency.

    See the full financial breakdown →
    61 3 9389 1911
    Websitehttps://www.csl.com